Skip to main content
Signal8

AH Bio Fund II, L.P.

SEC insider (Form 3/4/5 filer). CIK 0001725721. 10% Owner at Scribe Therapeutics, Inc. (SCTX). 3 reported Form 4/5 transactions since Sep 2024; latest on Jul 27, 2026. Located in MENLO PARK, CA.

Companies AH Bio Fund II, L.P. has filed insider reports for

  • Scribe Therapeutics, Inc. (SCTX): 10% Owner
AH Bio Fund II, L.P. profile photo

AH Bio Fund II, L.P.

CIK: 0001725721

Transaction Breakdown

Open Market Buys (P)1 (33.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (66.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Scribe Therapeutics, Inc. logo
SCTX

Scribe Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (3 total)

  • Scribe Therapeutics, Inc. logo
    SCTX

    Scribe Therapeutics, Inc.

    Jul 27, 2026
    Conversion
    Indirect
    2.1M shares-
  • Scribe Therapeutics, Inc. logo
    SCTX

    Scribe Therapeutics, Inc.

    Jul 27, 2026
    Conversion
    Indirect
    697.7K shares-
  • Scribe Therapeutics, Inc. logo
    SCTX

    Scribe Therapeutics, Inc.

    Jul 27, 2026
    Purchase
    Indirect
    333.3K shares at avg. $15.00$5.0M

1-3 of 3